NAGE vs SOPH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
NAGE demonstrates strong operational health with a Piotroski F-Score of 7/9 and a pristine balance sheet characterized by a very low Debt/Equity ratio (0.04). However, the stock is trading at a significant premium to its Graham Number ($2.08) and Intrinsic Value ($1.40), suggesting a valuation disconnect. While the company has successfully transitioned from historical losses to profitability—a rarity in the biotech sector—recent YoY earnings growth has plummeted by 41.6%. The conflict between a 'Strong Buy' analyst consensus and a completely bearish technical trend (0/100) warrants a cautious approach.
SOPH exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a profit margin of -102.24%. While the company maintains a strong gross margin (67.39%) and healthy revenue growth (22.40%), these are overshadowed by massive operational losses and a bearish insider sentiment. The disconnect between the 'Strong Buy' analyst consensus and the deteriorating fundamental health suggests a highly speculative valuation. Overall, the company is burning capital rapidly with no clear path to profitability in the immediate term.
Compare Another Pair
Related Comparisons
NAGE vs SOPH: Head-to-Head Comparison
This page compares Niagen Bioscience, Inc. (NAGE) and SOPHiA GENETICS SA (SOPH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.